|
|
||||||||||
|
J Am Coll Cardiol, 2003; 42:140-147, doi:10.1016/S0735-1097(03)00556-4 © 2003 by the American College of Cardiology Foundation |









* Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
Section on Heart Failure and Cardiac Transplant Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Cardiovascular Section, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA
Cardiology Department, Lady Davis Carmel Medical Center, Haifa, Israel
|| Cardiology Institute, Assaf-Harofeh Medical Center, Zerifin, Israel
¶ Department of Cardiology, Charite Hospital, Humboldt University, Berlin, Germany
# Division of Cardiology, University of Southern California School of Medicine, Los Angeles, California, USA
** Cardiology, San Francisco Veterans Affairs Medical Center/University of California at San Francisco, San Francisco, California, USA

Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
Manuscript received August 30, 2002; revised manuscript received December 14, 2002, accepted January 30, 2003.
* Reprint requests and correspondence: Dr. Guillermo Torre-Amione, Baylor College of Medicine Section of Cardiology, Texas Medical Center, One Baylor Plaza, Houston, Texas 77030, USA.
gtorre{at}bcm.tmc.edu
OBJECTIVES: We sought to investigate the efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized for acute heart failure (HF).
BACKGROUND: Tezosentan has been previously shown to improve hemodynamics in patients with stable chronic HF.
METHODS: In a double-blind fashion, 292 patients (cardiac index
2.5 l/min per m2 and pulmonary capillary wedge pressure (PCWP)
15 mm Hg) who were admitted to the hospital and in need of intravenous treatment for acute HF and central hemodynamic monitoring were randomized to 24-h intravenous treatment with tezosentan (50 or 100 mg/h) or placebo. Central hemodynamic variables, the dyspnea score, and safety variables were measured.
RESULTS: After 6 h of treatment, significantly greater increases in the cardiac index and decreases in PCWP were observed with both tezosentan dosages than with placebo (mean treatment effects at 0.38 and 0.37 l/min per m2 with 50 and 100 mg/h and 3.9 mm Hg for each dose, respectively; p < 0.0001). This effect was maintained during the remaining infusion and for
6 h after treatment cessation. A tendency for an improved dyspnea score and a decreased risk of clinical worsening was observed after 24 h of treatment with each tezosentan dose. Adverse events, more frequent with tezosentan than with placebo (headache, asymptomatic hypotension, early worsening of renal function, nausea, vomiting), were dose-related.
CONCLUSIONS: Intravenous tezosentan rapidly and effectively improved hemodynamics in these patients. The similar beneficial effects of the two dosages and the increased dose-related adverse events with the higher dosage suggest that the optimal dosing regimen is <50 mg/h.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
J. E. Udelson, C. Orlandi, J. Ouyang, H. Krasa, C. A. Zimmer, G. Frivold, W. H. Haught, S. Meymandi, C. Macarie, D. Raef, et al. Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1540 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Pang, J. G.F. Cleland, J. R. Teerlink, S. P. Collins, C. J. Lindsell, G. Sopko, W. F. Peacock, G. C. Fonarow, A. Z. Aldeen, J. D. Kirk, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach Eur. Heart J., March 2, 2008; 29(6): 816 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF] |
||||
![]() |
Additional Information JAMA, March 15, 2006; 295(11): E1 - E6. [Full Text] [PDF] |
||||
![]() |
S J Leslie, J C S Spratt, S P McKee, F E Strachan, D E Newby, D B Northridge, M A Denvir, and D J Webb Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure Heart, July 1, 2005; 91(7): 914 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade and F. Zannad Modern management of acute heart failure syndromes Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B3 - B7. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF] |
||||
![]() |
G. Cotter, Y. Moshkovitz, E. Kaluski, A. J. Cohen, H. Miller, D. Goor, and Z. Vered Accurate, Noninvasive Continuous Monitoring of Cardiac Output by Whole-Body Electrical Bioimpedance Chest, April 1, 2004; 125(4): 1431 - 1440. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |